Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.